Latest Insider Transactions at Hca Healthcare, Inc. (HCA)
This section provides a real-time view of insider transactions for Hca Healthcare, Inc. (HCA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HCA Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HCA Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2023
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Exercise of conversion of derivative security
|
Direct |
12,025
+17.65%
|
$565,175
$47.97 P/Share
|
|
Nov 10
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Bona fide gift
|
Indirect |
29,771
+50.0%
|
-
|
|
Nov 10
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Bona fide gift
|
Indirect |
29,771
-100.0%
|
-
|
|
Aug 14
2023
|
Bill B Rutherford CFO and EVP |
BUY
Bona fide gift
|
Indirect |
90,000
+42.74%
|
-
|
|
Aug 14
2023
|
Bill B Rutherford CFO and EVP |
SELL
Bona fide gift
|
Indirect |
49,500
-100.0%
|
-
|
|
Aug 14
2023
|
Bill B Rutherford CFO and EVP |
SELL
Bona fide gift
|
Direct |
40,500
-86.41%
|
-
|
|
Aug 14
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
5,204
-20.85%
|
$1,399,876
$269.12 P/Share
|
|
Aug 11
2023
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Open market or private sale
|
Direct |
1,500
-25.36%
|
$405,000
$270.0 P/Share
|
|
Aug 04
2023
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
205
-82.0%
|
-
|
|
Aug 03
2023
|
Mike A Marks EVP and CFO |
BUY
Bona fide gift
|
Indirect |
8,343
+16.91%
|
-
|
|
Aug 03
2023
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
8,343
-97.09%
|
-
|
|
Aug 03
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
2,916
-22.15%
|
$787,320
$270.0 P/Share
|
|
Aug 02
2023
|
Bill B Rutherford CFO and EVP |
BUY
Bona fide gift
|
Indirect |
49,500
+50.0%
|
-
|
|
Aug 02
2023
|
Bill B Rutherford CFO and EVP |
SELL
Bona fide gift
|
Direct |
49,500
-51.37%
|
-
|
|
Aug 01
2023
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
11,450
+29.99%
|
-
|
|
Aug 01
2023
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Direct |
11,450
-29.23%
|
-
|
|
May 12
2023
|
Richard A Hammett Group President |
SELL
Bona fide gift
|
Direct |
1,100
-7.4%
|
-
|
|
May 04
2023
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
12,511
+50.0%
|
-
|
|
May 04
2023
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Direct |
12,511
-3.89%
|
-
|
|
May 01
2023
|
Erol R Akdamar Group President |
BUY
Bona fide gift
|
Indirect |
42,484
+50.0%
|
-
|
|
May 01
2023
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
42,484
-100.0%
|
-
|
|
Apr 28
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
12,556
-30.37%
|
$3,565,904
$284.44 P/Share
|
|
Apr 28
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-19.7%
|
$1,757,301
$287.33 P/Share
|
|
Apr 28
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Exercise of conversion of derivative security
|
Direct |
8,844
+13.18%
|
$1,255,848
$142.15 P/Share
|
|
Apr 28
2023
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
3,500
-7.61%
|
$997,500
$285.0 P/Share
|
|
Apr 24
2023
|
Hugh F Johnston Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+24.62%
|
-
|
|
Apr 24
2023
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,187
+11.23%
|
-
|
|
Apr 24
2023
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+4.76%
|
-
|
|
Apr 24
2023
|
Andrea B Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+18.6%
|
-
|
|
Apr 24
2023
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+8.73%
|
-
|
|
Apr 24
2023
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,396
+10.26%
|
-
|
|
Apr 24
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
4,473
-16.74%
|
$1,288,224
$288.38 P/Share
|
|
Apr 24
2023
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+10.39%
|
-
|
|
Apr 24
2023
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+4.08%
|
-
|
|
Apr 24
2023
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+3.19%
|
-
|
|
Apr 24
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,464
-32.01%
|
$5,566,704
$286.25 P/Share
|
|
Apr 24
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,020
+34.5%
|
$3,234,020
$101.16 P/Share
|
|
Apr 14
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
2,687
-9.83%
|
$738,925
$275.0 P/Share
|
|
Apr 12
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,653
-11.79%
|
$993,616
$272.38 P/Share
|
|
Apr 12
2023
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,340
+16.99%
|
$513,540
$81.96 P/Share
|
|
Apr 10
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
2,539
-9.34%
|
$685,530
$270.0 P/Share
|
|
Apr 05
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,461
-11.29%
|
$937,931
$271.31 P/Share
|
|
Apr 05
2023
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+16.37%
|
$486,000
$81.96 P/Share
|
|
Apr 04
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
3,034
-10.96%
|
$804,010
$265.0 P/Share
|
|
Feb 17
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,441
-32.12%
|
$639,542
$262.84 P/Share
|
|
Feb 17
2023
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,600
+50.0%
|
-
|
|
Feb 17
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,844
-6.46%
|
$483,128
$262.84 P/Share
|
|
Feb 17
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
6,080
+17.55%
|
-
|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,356
-9.34%
|
$355,272
$262.84 P/Share
|
|
Feb 17
2023
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,560
+23.9%
|
-
|